Anastrozole
- Generic Name
- Anastrozole
- Brand Names
- Arimidex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N5
- CAS Number
- 120511-73-1
- Unique Ingredient Identifier
- 2Z07MYW1AZ
- Background
Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to letrozole, used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to exemestane, a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated ad...
- Indication
Anastrozole is indicated as adjunct therapy in the treatment of hormone receptor-positive early breast cancer in postmenopausal women, and as a first-line treatment for hormone receptor-positive (or hormone receptor-unknown) locally advanced or metastatic breast cancer in postmenopausal women. It may also be used in the treatment of advanced breast cancer in...
- Associated Conditions
- Advanced Breast Cancer, Invasive Early Breast Cancer, Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
- Associated Therapies
- -
Pulmonary Hypertension and Anastrozole Trial
- Conditions
- Interventions
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 84
- Registration Number
- NCT03229499
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Vanderbilt University, Nashville, Tennessee, United States
Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2022-01-06
- Lead Sponsor
- Palleos Healthcare GmbH
- Target Recruit Count
- 532
- Registration Number
- NCT03220178
- Locations
- 🇩🇪
University Hospital Mainz, Mainz, Germany
Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 37
- Registration Number
- NCT03219476
- Locations
- 🇺🇸
Froedtert Hospital, Milwaukee, Wisconsin, United States
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-06-07
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 19
- Registration Number
- NCT03179904
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 133
- Registration Number
- NCT03099174
- Locations
- 🇺🇸
University of California Los Angeles, Santa Monica, California, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-28
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 496
- Registration Number
- NCT02947685
- Locations
- 🇺🇸
University of Maryland - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02942355
- Locations
- 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- iOMEDICO AG
- Target Recruit Count
- 388
- Registration Number
- NCT02894398
- Locations
- 🇩🇪
Research Site, Wilhelmshaven, Germany
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT02779751
- Locations
- 🇫🇷
Hôpital Arnaud de Villeneuve - CHU Montpellier, Montpellier, Hérault, France
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Colorado School of Medicine, Aurora, Colorado, United States
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2016-05-06
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT02765373
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.